U.S. Stock: United Therapeutics Corp

By Andrew Stotz of Become A Better Investor
Wednesday, September 25, 2024 3:51 PM EDT

Company: United Therapeutics Corporation

Bloomberg ticker: UTHR US

Market cap: US$12,777m

Background: United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. The Company’s lead products are stable synthetic forms of prostacyclin and are delivered orally or subcutaneously.


World Class Benchmarking of United Therapeutics Corp

(Click on image to enlarge)

 

  • Profitable Growth rank of 1 was up compared to the prior period’s 2nd rank
  • This is World Class performance compared to 380 large Health Care companies worldwide
  • Profitability rank of 1 was better than its Growth rank of 3
  • Profitability rank of 1 was the same compared to the prior period’s 1st rank
  • This is World Class performance compared to peers
  • Growth rank of 3 was up compared to the prior period’s 4th rank
  • This is above average performance compared to peers

More By This Author:

Asian Stock: Bumi Armada
Asian Stock: GFPT
Asian Stock: Genting Berhad

Disclaimer: This content is for information purposes only. It is not intended to be investment advice. Readers should not consider statements made by the author(s) as formal recommendations and ...

more
How did you like this article? Let us know so we can better customize your reading experience.

Comments